# Clinical trial results:
# A Multicenter Post Marketing Surveillance Study to monitor the safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY conjugate vaccine(MenACWY-CRM) administered according to the prescribing information to healthy subjects from 2 months to 55 years of age in the Republic of South Korea.

## Summary

| | |
|---|---|
| EudraCT number | 2017-000166-30 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 22 January 2018 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 05 August 2018 |
| First version publication date | 05 August 2018 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | 205341 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, +(44) 2089904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, +(44) 2089904466, GSKClinicalSupportHD@gsk.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 14 May 2018 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 22 January 2018 |
| Global end of trial reached? | Yes |
| Global end of trial date | 22 January 2018 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study was to monitor the safety of MenACWY-CRM vaccine in subjects from 2 months to 55 years of age, as evaluated by:
- Local and systemic solicited adverse events reported from study Day 1 (day of vaccination) through study Day 7 post-vaccination;
- All unsolicited Adverse Events (AEs) reported from study Day 1 (day of vaccination) through study Day 7 post-vaccination;
- Medically attended Adverse Events reported from study Day 1 to study termination (Day 29/early termination).
- All Serious Adverse Events (SAEs) reported from study Day 1 to study termination (Day 29/early termination).

Protection of trial subjects:

All subjects were observed closely for at least 30 minutes in the clinic after vaccination, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccines. Study vaccines were administered only by personnel qualified to perform that function according to the routine clinical practice and under applicable local laws and regulations for the specific study site.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 15 March 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Korea, Republic of: 3948 |
| Worldwide total number of subjects | 3948 |
| EEA total number of subjects | 0 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 | 654 |

| | |
|---|---|
| months) | |
| Children (2-11 years) | 955 |
| Adolescents (12-17 years) | 302 |
| Adults (18-64 years) | 2035 |
| From 65 to 84 years | 2 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Healthy subjects from 2 months to 55 years of age were enrolled in 46 centres in South Korea.

### Pre-assignment

Screening details:

Out of the 3,948 subjects enrolled, only 3,939 subjects were exposed to vaccination as 1 subject did not receive a study vaccination and 8 subjects did not provide post vaccination safety data. Among 3939 subjects, 15 subjects are in the ≥ 56 age category (outside the range defined as per the protocol).

### Pre-assignment period milestones

| | |
|---|---|
| Number of subjects started | 3948 |
| Number of subjects completed | 3939 |

### Pre-assignment subject non-completion reasons

| | |
|---|---|
| Reason: Number of subjects | No safety data provided: 8 |
| Reason: Number of subjects | Did not receive study vaccination: 1 |

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Blinding implementation details:

This was an open- label study. No blinding methods were used

### Arms

| | |
|---|---|
| **Arm title** | MenACWY-CRM Group |

Arm description:

Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.

| | |
|---|---|
| Arm type | Safety surveillance |
| Investigational medicinal product name | MenACWY-CRM conjugate vaccine (Menveo) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

one intramuscular injection of MenACWY-CRM vaccine at Day 1

| **Number of subjects in period 1[1]** | MenACWY-CRM Group |
|---|---|
| Started | 3939 |
| Completed | 3888 |
| Not completed | 51 |
| Consent withdrawn by subject | 22 |
| Inappropriate enrollment | 18 |
| Lost to follow-up | 10 |
| withdrawal and inappropriate enrollment | 1 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: The number of subjects reported in the baseline period are based on the exposed set (3939). Out of 3948 subjects enrolled, 8 subjects did not report safety data and 1 subject did not receive the study vaccination.

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | MenACWY-CRM Group |
| Reporting group description: | |
| Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care. | |

| Reporting group values | MenACWY-CRM Group | Total | |
|---|---|---|---|
| Number of subjects | 3939 | 3939 | |
| Age categorical<br>Units: Subjects | | | |
| 2- 23 months | 654 | 654 | |
| 2-5 years | 551 | 551 | |
| 6-10 years | 339 | 339 | |
| 11-18 years | 433 | 433 | |
| 19-34 years | 1286 | 1286 | |
| 35 - 55 years | 661 | 661 | |
| ≥ 56 years | 15 | 15 | |
| Age continuous<br>Units: years | | | |
| log mean | 18.37 | | |
| standard deviation | ± 15.40 | - | |
| Gender categorical<br><br>Units: Subjects | | | |
| Female | 2181 | 2181 | |
| Male | 1758 | 1758 | |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| Asian | 3937 | 3937 | |
| Caucasian | 1 | 1 | |
| Hispanic | 1 | 1 | |

## End points

### End points reporting groups

| Reporting group title | MenACWY-CRM Group |
|---|---|

Reporting group description:

Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.

### Primary: Number of subjects reporting any local and systemic solicited Adverse Events (AEs)

| End point title | Number of subjects reporting any local and systemic solicited Adverse Events (AEs)[1] |
|---|---|

End point description:

Assessed solicited local AEs include: injection site erythema, injection site induration, injection site tenderness, injection site pain. Assessed solicited systemic AEs include: change in eating habits, sleepiness, irritability, rash, vomiting, diarrhea, fever, chills, nausea, malaise, generalized myalgia, generalized arthralgia, headache. "Any" is defined as any report of the specified symptom irrespective of intensity grade. Subjects from 2 months to 55 years of age were evaluated for the outcome measure. This analysis was performed on the Safety per protocol set, which included all enrolled subjects who signed an informed consent, underwent screening, received a subject number, received a study vaccination and provided post vaccination data, excluding 19 subjects from safety set with protocol violations.

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 (day of vaccination) to Day 7 post vaccination

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this endpoint was descriptive analysis. Therefore, no statistical analyses have been specified for this endpoint.

| End point values | MenACWY-CRM Group | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3920 | | | |
| Units: Participants | | | | |
| Any injection site tenderness,2 - 23 months(N-653) | 67 | | | |
| Any injection site erythema, 2 - 23 months(N-653) | 32 | | | |
| Any injection site induration,2 - 23 months(N-653) | 28 | | | |
| Any change in eating habbits, 2 - 23 months(N-653) | 110 | | | |
| Any sleepiness, 2 - 23 months(N-653) | 126 | | | |
| Any irritability, 2 - 23 months(N-653) | 219 | | | |
| Any vomiting, 2 - 23 months(N-653) | 66 | | | |
| Any diarrhea, 2 - 23 months(N-653) | 82 | | | |
| Any rash, 2 - 23 months(N-653) | 20 | | | |
| Any fever, 2 - 23 months(N-653) | 57 | | | |
| Any injection site tenderness, 2 - 5 years(N-551) | 135 | | | |
| Any injection site erythema, 2 - 5 years(N-551) | 71 | | | |

| | | | | |
|---|---|---|---|---|
| Any injection site induration, 2 - 5 years(N-551) | 49 | | | |
| Any change in eating habits, 2 - 5 years(N-551) | 22 | | | |
| Any sleepiness, 2 - 5 years(N-551) | 17 | | | |
| Any irritability, 2 - 5 years(N-551) | 35 | | | |
| Any vomiting, 2 - 5 years(N-551) | 4 | | | |
| Any diarrhea, 2 - 5 years(N-551) | 7 | | | |
| Any rash, 2 - 5 years(N-551) | 18 | | | |
| Any fever, 2 - 5 years(N-551) | 12 | | | |
| Any injection site tenderness, 6 - 10 years(N-338) | 108 | | | |
| Any injection site erythema, 6 - 10 years(N-338) | 53 | | | |
| Any injection site induration, 6 - 10 years(N-338) | 45 | | | |
| Any chills, 6 - 10 years(N-338) | 7 | | | |
| Any nausea, 6 - 10 years(N-338) | 7 | | | |
| Any malaise, 6 - 10 years(N-338) | 5 | | | |
| Any myalgia, 6 - 10 years(N-338) | 6 | | | |
| Any arthralgia, 6 - 10 years(N-338) | 6 | | | |
| Any headache, 6 - 10 years(N-338) | 11 | | | |
| Any rash, 6 - 10 years(N-338) | 10 | | | |
| Any fever, 6 - 10 years(N-338) | 9 | | | |
| Any injection site tenderness, 11-18 years(N-431) | 91 | | | |
| Any injection site erythema, 11 - 18 years(N-431) | 17 | | | |
| Any injection site induration, 11- 18 years(N-431) | 21 | | | |
| Any chills, 11 - 18 years(N-431) | 9 | | | |
| Any nausea, 11 - 18 years(N-431) | 4 | | | |
| Any malaise, 11 - 18 years(N-431) | 9 | | | |
| Any myalgia, 11 - 18 years(N-431) | 12 | | | |
| Any arthralgia, 11 - 18 years(N-431) | 5 | | | |
| Any headache, 11 - 18 years(N-431) | 12 | | | |
| Any rash, 11 - 18 years(N-431) | 6 | | | |
| Any fever, 11 - 18 years(N-431) | 4 | | | |
| Any injenction site tenderness,19-34 years(N-1286) | 214 | | | |
| Any injection site erythema, 19 - 34 years(N-1286) | 14 | | | |
| Any injection site induration,19 - 34 years(N-1286 | 9 | | | |
| Any chills, 19 - 34 years(N-1286) | 7 | | | |
| Any nausea, 19 - 34 years(N-1286) | 6 | | | |
| Any malaise, 19 - 34 years(N-1286) | 20 | | | |
| Any myalgia, 19 - 34 years(N-1286) | 21 | | | |
| Any arthralgia, 19 - 34 years(N-1286) | 8 | | | |
| Any headache, 19 - 34 years(N-1286) | 29 | | | |
| Any rash, 19 - 34 years(N-1286) | 13 | | | |
| Any fever, 19 - 34 years(N-1286) | 3 | | | |
| Any injection site tenderness, 35-55 years(N-661) | 174 | | | |
| Any injection site erythema, 35 - 55 years(N-661) | 7 | | | |

| | | | | |
|---|---|---|---|---|
| Any injection site induration, 35 -55 years(N-661) | 6 | | | |
| Any chills, 35 - 55 years(N-661) | 7 | | | |
| Any nausea, 35 - 55 years(N-661) | 9 | | | |
| Any malaise, 35 - 55 years(N-661) | 16 | | | |
| Any myalgia, 35 - 55 years(N-661) | 23 | | | |
| Any arthralgia, 35 - 55 years(N-661) | 15 | | | |
| Any headache, 35 - 55 years(N-661) | 19 | | | |
| Any rash, 35 - 55 years(N-661) | 6 | | | |
| Any fever, 35 - 55 years(N-661) | 2 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects reporting any unsolicited adverse events (AEs)

| End point title | Number of subjects reporting any unsolicited adverse events (AEs)[2] |
|---|---|

End point description:

An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment. All unsolicited AEs reported from day 1 to day 7 post vaccination were assessed. "Any" is defined as any report of the specified symptom irrespective of intensity grade.
Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
This analysis was performed on the Safety per protocol set, which included all enrolled subjects who signed an informed consent, underwent screening, received a subject number, received a study vaccination and provided post vaccination data, excluding 19 subjects from safety set with protocol violations.

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 (day of vaccination) to Day 7 post vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this endpoint was descriptive analysis. Therefore, no statistical analyses have been specified for this endpoint.

| **End point values** | MenACWY-CRM Group | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3920 | | | |
| Units: Participants | | | | |
| 2 - 23 Months(N-653) | 82 | | | |
| 2 - 5 Years(N-551) | 56 | | | |
| 6 - 10 Years(N-338) | 18 | | | |
| 11 - 18 Years(N-431) | 8 | | | |
| 19 - 34 Years(N-1286) | 17 | | | |
| 35 - 55 Years(N-661) | 5 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects reporting medically attended AEs (MAAEs)

| End point title | Number of subjects reporting medically attended AEs |
|---|---|

End point description:

MAAEs are defined as events that require a physician's visit or an emergency room visit. All reported MAAEs from day 1 to day 29 were assessed. Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
This analysis was performed on the Safety per protocol set, which included all enrolled subjects who signed an informed consent, underwent screening, received a subject number, received a study vaccination and provided post vaccination data, excluding 19 subjects from safety set with protocol violations.

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 (day of vaccination) to study termination (Day 29/early termination)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this endpoint was descriptive analysis. Therefore, no statistical analyses have been specified for this endpoint.

| End point values | MenACWY-CRM Group | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3920 | | | |
| Units: Participants | | | | |
| 2 - 23 Months(N-653) | 238 | | | |
| 2 - 5 Years(N-551) | 120 | | | |
| 6 - 10 Years(N-338) | 28 | | | |
| 11 - 18 Years(N-431) | 20 | | | |
| 19 - 34 Years(N-1286) | 16 | | | |
| 35 - 55 Years(N-661) | 5 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects reporting serious AEs (SAEs)

| End point title | Number of subjects reporting serious AEs (SAEs)[4] |
|---|---|

End point description:

SAE is defined as any untoward medical occurrence that at any dose results in death,is life-threatening;it doesnot refer to an event which hypothetically might have caused death if it were more severe,requires or prolongs subject’s hospitalization,results in persistent/significant disability/incapacity,results in congenital anomaly/birth defect,is an important and significant medical event that may not be immediately life threatening/resulting in death/hospitalization but,based upon appropriate medical judgment,may jeopardize the subject/may require intervention to prevent one of the other outcomes listed above.Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
This analysis was performed on the Safety per protocol set,which included all enrolled subjects who signed an informed consent,underwent screening,received a subject number,received a study vaccination & provided post vaccination data,excluding 19 subjects from safety set with protocol

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 (day of vaccination) to study termination (Day 29/early termination)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this endpoint was descriptive analysis. Therefore, no statistical analyses have been specified for this endpoint.

| **End point values** | MenACWY-CRM Group | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 3920 | | | |
| Units: Participants | | | | |
| 2 - 23 Months(N-653) | 3 | | | |
| 2 - 5 Years(N-551) | 3 | | | |
| 6 - 10 Years(N-338) | 0 | | | |
| 11 - 18 Years(N-431) | 2 | | | |
| 19 - 34 Years(N-1286) | 0 | | | |
| 35 - 55 Years(N-661) | 0 | | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited and unsolicited AEs were reported from Day 1 to Day 7. MAAEs and SAEs were reported from study day 1 to study termination (Day 29/early termination).

Adverse event reporting additional description:

Total number of subjects at risk for SAEs, all cause mortality and FAEs were analyzed from the Safety set (including 15 subjects of ≥ 56 years age category).

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 21.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | MenACWY-CRM Group |

Reporting group description:

Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.

| Serious adverse events | MenACWY-CRM Group | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 8 / 3939 (0.20%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Bronchiolitis | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|---|---|---|
| Pneumonia | | | |
| subjects affected / exposed | 4 / 3939 (0.10%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| **Non-serious adverse events** | MenACWY-CRM Group | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1379 / 3939 (35.01%) | | |
| Vascular disorders | | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Orthostatic hypotension-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| Injection site tenderness-Solicited local AE | Additional description: This symptom was assessed as a solicited local AE. | | |
| subjects affected / exposed | 202 / 3939 (5.13%) | | |
| occurrences (all) | 202 | | |
| Injection site pain-Solicited Local AE | Additional description: This symptom was assessed as a solicited local AE. | | |
| subjects affected / exposed | 592 / 3939 (15.03%) | | |
| occurrences (all) | 592 | | |
| Injection site erythema-Solicited local AE | Additional description: This symptom was assessed as a solicited local AE. | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 195 / 3939 (4.95%) | | |
| occurrences (all) | 195 | | |
| Injection site induration-solicited local AE | Additional description: This symptom was assessed as a solicited local AE. | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 158 / 3939 (4.01%) | | |
| occurrences (all) | 158 | | |
| Diarrhea-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 89 / 3939 (2.26%) | | |
| occurrences (all) | 89 | | |
| Chills-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 31 / 3939 (0.79%) | | |
| occurrences (all) | 31 | | |
| Nausea-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 28 / 3939 (0.71%) | | |
| occurrences (all) | 28 | | |
| Malaise-solicited general AE | Additional description: This symptom was assessed as a solicited general AE, | | |
| subjects affected / exposed | 53 / 3939 (1.35%) | | |
| occurrences (all) | 53 | | |
| Myalgia-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 64 / 3939 (1.62%) | | |
| occurrences (all) | 64 | | |
| Arthralgia-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 34 / 3939 (0.86%) | | |
| occurrences (all) | 34 | | |
| Fever-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 87 / 3939 (2.21%) | | |
| occurrences (all) | 87 | | |
| Pyrexia | | | |
| subjects affected / exposed | 8 / 3939 (0.20%) | | |
| occurrences (all) | 8 | | |
| Injection site erythema | | | |
| subjects affected / exposed | 9 / 3939 (0.23%) | | |
| occurrences (all) | 9 | | |
| Injection site induration | | | |
| subjects affected / exposed | 7 / 3939 (0.18%) | | |
| occurrences (all) | 7 | | |
| Injection site pruritus | | | |
| subjects affected / exposed | 7 / 3939 (0.18%) | | |
| occurrences (all) | 7 | | |
| Injection site pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Injection site warmth | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Injection site bruising | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Injection site swelling | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Pyrexia-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 15 / 3939 (0.38%) | | |
| occurrences (all) | 17 | | |
| Injection site erythema-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Injection site pruritus-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Oedema peripheral-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Chest pain-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Injection site rash-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Injection site swelling-MAAE | Additional description: This symptom was assessed as a MAAE. | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Immune system disorders | | | |
| Atopy | | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Reproductive system and breast disorders | | | |
| Prostatic cyst | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Prostatic cyst-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Asthma | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Cough | | | |
| subjects affected / exposed | 4 / 3939 (0.10%) | | |
| occurrences (all) | 4 | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Nasal congestion | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Productive cough | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Oropharyngeal pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Rhinitis allergic-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 18 / 3939 (0.46%) | | |
| occurrences (all) | 18 | | |
| Asthma-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 8 / 3939 (0.20%) | | |
| occurrences (all) | 8 | | |
| Cough-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Rhinorrhoea-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Nasal congestion-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Productive cough-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Psychiatric disorders | | | |
| Eating disorder-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 132 / 3939 (3.35%) | | |
| occurrences (all) | 132 | | |
| Irritability-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 254 / 3939 (6.45%) | | |
| occurrences (all) | 254 | | |
| Eating disorder | | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Irritability | | | |
| subjects affected / exposed | 4 / 3939 (0.10%) | | |
| occurrences (all) | 4 | | |
| Eating disorder-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |

| | | | |
|---|---|---|---|
| Irritability-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Injury, poisoning and procedural complications | | | |
| Arthropod bite | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Laceration | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 2 | | |
| Nail injury | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Arthropod bite-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Contusion-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Laceration-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 2 | | |
| Ligament sprain-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Muscle strain-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Skin abrasion-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Nervous system disorders | | | |
| Sleepiness-Solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 143 / 3939 (3.63%) | | |
| occurrences (all) | 143 | | |
| Headache-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 73 / 3939 (1.85%) | | |
| occurrences (all) | 73 | | |
| Headache | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Burning sensation | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Dizziness-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Somnolence | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| sleepiness | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Blood and lymphatic system disorders | | | |
| Lymphadentitis | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Anaemia-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Iron deficiency anaemia-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Lymphadenitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Ear and labyrinth disorders | | | |
| Ear pain-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Eye disorders | | | |

| | | | |
|---|---|---|---|
| Conjunctivitis allergic | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Eye discharge | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Conjunctivitis allergic-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Keratitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal disorders | | | |
| Vomiting-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 70 / 3939 (1.78%) | | |
| occurrences (all) | 70 | | |
| Enteritis | | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Vomiting | | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Constipation | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Stomatitis | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Abdominal pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 4 / 3939 (0.10%) | | |
| occurrences (all) | 4 | | |
| Colitis | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Dental caries | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Gastritis erosive | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Enteritis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 22 / 3939 (0.56%) | | |
| occurrences (all) | 23 | | |
| Diarrhoea-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 7 / 3939 (0.18%) | | |
| occurrences (all) | 7 | | |
| Vomiting-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 8 / 3939 (0.20%) | | |
| occurrences (all) | 8 | | |
| Constipation-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 7 / 3939 (0.18%) | | |
| occurrences (all) | 7 | | |
| Stomatitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 7 / 3939 (0.18%) | | |
| occurrences (all) | 7 | | |
| Gastritis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Abdominal pain-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Colitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Chronic gastritis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Dental caries-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Gastritis erosive-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Gastrooesophageal reflux disease-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Irritable bowel syndrome-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Rash-solicited general AE | Additional description: This symptom was assessed as a solicited general AE. | | |
| subjects affected / exposed | 74 / 3939 (1.88%) | | |
| occurrences (all) | 74 | | |
| Dermatitis atopic | | | |
| subjects affected / exposed | 7 / 3939 (0.18%) | | |
| occurrences (all) | 7 | | |
| Dermatitis | | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Urticaria | | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Dermatitis contact | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Dermatitis allergic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Rash | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Cold sweat | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Dyshidrotic eczema | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Eczema | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Generalised erythema | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Pruritus | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Dermatitis atopic-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 20 / 3939 (0.51%) | | |
| occurrences (all) | 20 | | |
| Dermatitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 11 / 3939 (0.28%) | | |
| occurrences (all) | 11 | | |
| Urticaria-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 10 / 3939 (0.25%) | | |
| occurrences (all) | 12 | | |
| Dermatitis contact-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 8 / 3939 (0.20%) | | |
| occurrences (all) | 8 | | |
| Blister-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Dermatitis allergic-MAAE | Additional description: This symptom was assessed as a MAAE. | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Dermatitis diaper-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Eczema-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Generalised erythema-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Miliaria-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Seborrhoeic dermatitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Renal cyst | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Tubulointerstitial nephritis | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Haematuria-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Renal cyst-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Tubulointerstitial nephritis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |

| | | | |
|---|---|---|---|
| Musculoskeletal and connective tissue disorders | | | |
| Myalgia | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Arthralgia-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Neck pain-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 21 / 3939 (0.53%) | | |
| occurrences (all) | 21 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 31 / 3939 (0.79%) | | |
| occurrences (all) | 31 | | |
| Pharyngitis | | | |
| subjects affected / exposed | 13 / 3939 (0.33%) | | |
| occurrences (all) | 13 | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Bronchiolitis | | | |
| subjects affected / exposed | 11 / 3939 (0.28%) | | |
| occurrences (all) | 11 | | |
| Otitis media | | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Pneumonia | | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Rhinitis | | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Conjunctivitis | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 4 / 3939 (0.10%) | | | |
| occurrences (all) | 4 | | | |
| Tonsillitis | | | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | | |
| occurrences (all) | 6 | | | |
| Upper respiratory tract infection | | | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | | |
| occurrences (all) | 3 | | | |
| Influenza | | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | | |
| occurrences (all) | 2 | | | |
| Cellulitis | | | | |
| subjects affected / exposed | 4 / 3939 (0.10%) | | | |
| occurrences (all) | 4 | | | |
| Acute sinusitis | | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | | |
| occurrences (all) | 2 | | | |
| Herpangina | | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | | |
| occurrences (all) | 2 | | | |
| Laryngitis | | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | | |
| occurrences (all) | 2 | | | |
| Viral pharyngitis | | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | | |
| occurrences (all) | 1 | | | |
| Cystitis | | | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | | |
| occurrences (all) | 2 | | | |
| Oral herpes | | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | | |
| occurrences (all) | 1 | | | |
| Periodontitis | | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | | |
| occurrences (all) | 1 | | | |
| Pharyngitis streptococcal | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Bronchitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 94 / 3939 (2.39%) | | |
| occurrences (all) | 100 | | |
| Nasopharyngitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 82 / 3939 (2.08%) | | |
| occurrences (all) | 93 | | |
| Pharyngitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 40 / 3939 (1.02%) | | |
| occurrences (all) | 42 | | |
| Gastroenteritis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 30 / 3939 (0.76%) | | |
| occurrences (all) | 31 | | |
| Bronchiolitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 28 / 3939 (0.71%) | | |
| occurrences (all) | 29 | | |
| Otitis media-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 22 / 3939 (0.56%) | | |
| occurrences (all) | 22 | | |
| Pneumonia-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 15 / 3939 (0.38%) | | |
| occurrences (all) | 16 | | |
| Rhinitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 13 / 3939 (0.33%) | | |
| occurrences (all) | 13 | | |
| Conjunctivitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 12 / 3939 (0.30%) | | |
| occurrences (all) | 12 | | |
| Tonsillitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 17 / 3939 (0.43%) | | |
| occurrences (all) | 17 | | |
| Upper respiratory tract infection- | Additional description: This symptom was assessed as a MAAE. | | |

| | | | |
|---|---|---|---|
| MAAE | | | |
| subjects affected / exposed | 11 / 3939 (0.28%) | | |
| occurrences (all) | 11 | | |
| Influenza-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 8 / 3939 (0.20%) | | |
| occurrences (all) | 8 | | |
| Cellulitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 6 / 3939 (0.15%) | | |
| occurrences (all) | 6 | | |
| Acute sinusitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Impetigo-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 5 / 3939 (0.13%) | | |
| occurrences (all) | 5 | | |
| Herpes dermatitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 4 / 3939 (0.10%) | | |
| occurrences (all) | 4 | | |
| Otitis media acute-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 4 / 3939 (0.10%) | | |
| occurrences (all) | 4 | | |
| Hand-foot-and-mouth disease-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Herpangina-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Laryngitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Oral candidiasis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |
| Viral pharyngitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 3 / 3939 (0.08%) | | |
| occurrences (all) | 3 | | |

| | | | |
|---|---|---|---|
| Cystitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Oral herpes-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Pharyngitis bacterial-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Pharyngotonsillitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Tracheitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 2 / 3939 (0.05%) | | |
| occurrences (all) | 2 | | |
| Bacterial infection-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Croup infectious-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Exanthema subitum-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal infection-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Hordeolum-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Periodontitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Pharyngitis streptococcal-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |

| | | | |
|---|---|---|---|
| Sinusitis-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Urinary tract infection-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Metabolism and nutrition disorders | | | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |
| Vitamin D deficiency-MAAE | Additional description: This symptom was assessed as a MAAE. | | |
| subjects affected / exposed | 1 / 3939 (0.03%) | | |
| occurrences (all) | 1 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 22 May 2013 | Rationale for change:<br>Change in target population from 11-55 years of age to 2-55 years of age.<br>Allow Assent Form provided to minors when requested by IRBs.<br>Change in the solicited local and systemic events description.<br>Exclusion criteria numbered.<br>Change of Korea Food and Drug Administration (KFDA) to Ministry of Food and Drug Safety (MFDS) |
| 22 October 2014 | Rationale for change:<br>Change in the location of the injection including infants.<br>Change in the study population, adding infants from 2 to 23 months.<br>Text added to clarify the procedure of infant vaccination.<br>Inclusion of infants in standard temperature measurement.<br>Text included to ensure that infants were not enrolled more than once.<br>Spontaneous reporting applied to this PMS studies.<br>Procedure correction involving the CRO instead of NVD.<br>Clarification that additional SAP will be performed to follow ICH requirements. |
| 12 May 2015 | Rationale for change:<br>Text included- For subjects 2-23 months of age, the parents will also be asked to consent for surveillance after subsequent vaccinations.<br>Some texts changed to align with Korean Heath Authorities.<br>Study time and events table was modified to include infant subjects.<br>Clarification of study participation duration. |
| 25 August 2015 | Rationale for change:<br>Due to change of Marketing Authorization Holder from Novartis Vaccines to GSK Vaccines, the document was revised to change name of Sponsor. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported